X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA CIPLA AJANTA PHARMA/
CIPLA
 
P/E (TTM) x 18.2 38.8 46.9% View Chart
P/BV x 4.2 4.0 104.7% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 AJANTA PHARMA   CIPLA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
CIPLA
Mar-17
AJANTA PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,818622 292.3%   
Low Rs1,106458 241.3%   
Sales per share (Unadj.) Rs239.5181.9 131.7%  
Earnings per share (Unadj.) Rs52.812.9 410.2%  
Cash flow per share (Unadj.) Rs59.529.3 203.0%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs230.0155.7 147.7%  
Shares outstanding (eoy) m88.77804.51 11.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.13.0 205.6%   
Avg P/E ratio x27.742.0 66.0%  
P/CF ratio (eoy) x24.618.4 133.4%  
Price / Book Value ratio x6.43.5 183.3%  
Dividend payout %015.5 0.0%   
Avg Mkt Cap Rs m129,782434,516 29.9%   
No. of employees `0006.823.0 29.5%   
Total wages/salary Rs m3,76526,338 14.3%   
Avg. sales/employee Rs Th3,128.46,349.1 49.3%   
Avg. wages/employee Rs Th554.01,143.0 48.5%   
Avg. net profit/employee Rs Th689.7449.3 153.5%   
INCOME DATA
Net Sales Rs m21,258146,302 14.5%  
Other income Rs m2422,287 10.6%   
Total revenues Rs m21,499148,589 14.5%   
Gross profit Rs m6,58424,758 26.6%  
Depreciation Rs m59613,229 4.5%   
Interest Rs m41,594 0.3%   
Profit before tax Rs m6,22612,222 50.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5391,798 85.6%   
Profit after tax Rs m4,68610,354 45.3%  
Gross profit margin %31.016.9 183.0%  
Effective tax rate %24.714.7 168.1%   
Net profit margin %22.07.1 311.5%  
BALANCE SHEET DATA
Current assets Rs m12,23687,370 14.0%   
Current liabilities Rs m3,46133,081 10.5%   
Net working cap to sales %41.337.1 111.3%  
Current ratio x3.52.6 133.9%  
Inventory Days Days6087 69.2%  
Debtors Days Days8462 135.6%  
Net fixed assets Rs m11,140111,567 10.0%   
Share capital Rs m1771,609 11.0%   
"Free" reserves Rs m20,237123,645 16.4%   
Net worth Rs m20,414125,254 16.3%   
Long term debt Rs m1036,454 0.0%   
Total assets Rs m24,486209,532 11.7%  
Interest coverage x1,519.48.7 17,528.5%   
Debt to equity ratio x00.3 0.2%  
Sales to assets ratio x0.90.7 124.3%   
Return on assets %19.25.7 335.9%  
Return on equity %23.08.3 277.7%  
Return on capital %30.58.5 358.8%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m11,66751,066 22.8%   
Fx outflow Rs m1,61617,678 9.1%   
Net fx Rs m10,05233,388 30.1%   
CASH FLOW
From Operations Rs m2,85423,824 12.0%  
From Investments Rs m-2,604-13,127 19.8%  
From Financial Activity Rs m-2-13,239 0.0%  
Net Cashflow Rs m248-2,478 -10.0%  

Share Holding

Indian Promoters % 73.8 16.0 461.3%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 1.6 12.2 12.7%  
FIIs % 7.6 23.7 32.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.0 26.2 64.9%  
Shareholders   20,968 161,166 13.0%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 218 Points Lower; Tata Steel & Tata Motors Top Losers(Closing)

Indian share markets ended lower in the final hour of the trade. At the closing bell, the BSE Sensex finished lower by 218 points and the NSE Nifty finished down by 82 points.

Related Views on News

SUN PHARMA plunges by 5%; BSE HEALTHCARE Index Down 3.4%

Jul 16, 2018 | Updated on Jul 16, 2018

SUN PHARMA share price has plunged by 5% and its Current Market Price is Rs 562. The BSE HEALTHCARE is down by 3.39%. The top gainers in the BSE HEALTHCARE Index are NARAYANA HRUDAYALAYA LTD (up 2.07%) and JUBILANT LIFE SCIENCES (up 1.80%). The top losers are SUN PHARMA (down 5.10%) and AJANTA PHARMA (down 5.30%).

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8%

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Has A Bank Ever Told You Its Deposits are Riskier than Stocks? These Should Have...(The 5 Minute Wrapup)

Jul 3, 2018

Left on their own, the banks would possibly have to mark down the value of deposits by 90% to 100%.

The Real Truth About India's FDI, Beyond WhatsApp(Vivek Kaul's Diary)

Jul 4, 2018

The FDI numbers do not look very impressive once we adjust for repatriations as well as the overall growth in the economy.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jul 16, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - DR. REDDYS LAB COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS